Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer.

Sano D, Xie TX, Ow TJ, Zhao M, Pickering CR, Zhou G, Sandulache VC, Wheeler DA, Gibbs RA, Caulin C, Myers JN.

Clin Cancer Res. 2011 Nov 1;17(21):6658-70. doi: 10.1158/1078-0432.CCR-11-0046. Epub 2011 Sep 8.

2.

TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.

Skinner HD, Sandulache VC, Ow TJ, Meyn RE, Yordy JS, Beadle BM, Fitzgerald AL, Giri U, Ang KK, Myers JN.

Clin Cancer Res. 2012 Jan 1;18(1):290-300. doi: 10.1158/1078-0432.CCR-11-2260. Epub 2011 Nov 16.

3.

TP53 mutations and survival in squamous-cell carcinoma of the head and neck.

Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, Ridge JA, Goodwin J, Kenady D, Saunders J, Westra W, Sidransky D, Koch WM.

N Engl J Med. 2007 Dec 20;357(25):2552-61.

4.

TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma.

Heaton CM, Durr ML, Tetsu O, van Zante A, Wang SJ.

Laryngoscope. 2014 Jul;124(7):E267-73. doi: 10.1002/lary.24595. Epub 2014 Feb 20.

PMID:
24431303
5.

Serine substitution of proline at codon 151 of TP53 confers gain of function activity leading to anoikis resistance and tumor progression of head and neck cancer cells.

Xie TX, Zhou G, Zhao M, Sano D, Jasser SA, Brennan RG, Myers JN.

Laryngoscope. 2013 Jun;123(6):1416-23. doi: 10.1002/lary.23846. Epub 2013 Apr 26.

6.

An orthotopic nude mouse model of oral tongue squamous cell carcinoma.

Myers JN, Holsinger FC, Jasser SA, Bekele BN, Fidler IJ.

Clin Cancer Res. 2002 Jan;8(1):293-8.

7.

Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.

Osman AA, Monroe MM, Ortega Alves MV, Patel AA, Katsonis P, Fitzgerald AL, Neskey DM, Frederick MJ, Woo SH, Caulin C, Hsu TK, McDonald TO, Kimmel M, Meyn RE, Lichtarge O, Myers JN.

Mol Cancer Ther. 2015 Feb;14(2):608-19. doi: 10.1158/1535-7163.MCT-14-0735-T. Epub 2014 Dec 10.

8.

Heterogeneous tumor stromal microenvironments of oral squamous cell carcinoma cells in tongue and nodal metastatic lesions in a xenograft mouse model.

Shirako Y, Taya Y, Sato K, Chiba T, Imai K, Shimazu Y, Aoba T, Soeno Y.

J Oral Pathol Med. 2015 Oct;44(9):656-68. doi: 10.1111/jop.12318. Epub 2015 Mar 13.

PMID:
25765182
9.

Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study.

Peltonen JK, Vähäkangas KH, Helppi HM, Bloigu R, Pääkkö P, Turpeenniemi-Hujanen T.

Head Neck Oncol. 2011 Apr 22;3:20. doi: 10.1186/1758-3284-3-20.

10.

TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.

Zhou G, Liu Z, Myers JN.

J Cell Biochem. 2016 Dec;117(12):2682-2692. doi: 10.1002/jcb.25592. Epub 2016 Jun 3. Review.

11.

Heat shock protein and p53 expression in head and neck squamous cell carcinoma.

Gandour-Edwards R, Trock BJ, Gumerlock P, Donald PJ.

Otolaryngol Head Neck Surg. 1998 May;118(5):610-5.

PMID:
9591858
12.

The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer.

Wichmann G, Rosolowski M, Krohn K, Kreuz M, Boehm A, Reiche A, Scharrer U, Halama D, Bertolini J, Bauer U, Holzinger D, Pawlita M, Hess J, Engel C, Hasenclever D, Scholz M, Ahnert P, Kirsten H, Hemprich A, Wittekind C, Herbarth O, Horn F, Dietz A, Loeffler M; Leipzig Head and Neck Group (LHNG).

Int J Cancer. 2015 Dec 15;137(12):2846-57. doi: 10.1002/ijc.29649. Epub 2015 Jul 6.

13.

TP53 gene mutations and CCND1 gene amplification in head and neck squamous cell carcinoma cell lines.

Xu L, Davidson BJ, Murty VV, Li RG, Sacks PG, Garin-Chesa P, Schantz SP, Chaganti RS.

Int J Cancer. 1994 Nov 1;59(3):383-7.

PMID:
7927946
14.

Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.

Ganci F, Sacconi A, Bossel Ben-Moshe N, Manciocco V, Sperduti I, Strigari L, Covello R, Benevolo M, Pescarmona E, Domany E, Muti P, Strano S, Spriano G, Fontemaggi G, Blandino G.

Ann Oncol. 2013 Dec;24(12):3082-8. doi: 10.1093/annonc/mdt380. Epub 2013 Oct 9.

15.

Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.

Gadhikar MA, Sciuto MR, Alves MV, Pickering CR, Osman AA, Neskey DM, Zhao M, Fitzgerald AL, Myers JN, Frederick MJ.

Mol Cancer Ther. 2013 Sep;12(9):1860-73. doi: 10.1158/1535-7163.MCT-13-0157. Epub 2013 Jul 9.

16.

Temporal characterization of lymphatic metastasis in an orthotopic mouse model of oral cancer.

Szaniszlo P, Fennewald SM, Qiu S, Kantara C, Shilagard T, Vargas G, Resto VA.

Head Neck. 2014 Nov;36(11):1638-47. doi: 10.1002/hed.23500. Epub 2014 Jan 27.

17.

Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma.

Lindenbergh-van der Plas M, Brakenhoff RH, Kuik DJ, Buijze M, Bloemena E, Snijders PJ, Leemans CR, Braakhuis BJ.

Clin Cancer Res. 2011 Jun 1;17(11):3733-41. doi: 10.1158/1078-0432.CCR-11-0183. Epub 2011 Apr 5.

18.

Disruption of the AKT pathway inhibits metastasis in an orthotopic model of head and neck squamous cell carcinoma.

Knowles JA, Golden B, Yan L, Carroll WR, Helman EE, Rosenthal EL.

Laryngoscope. 2011 Nov;121(11):2359-65. doi: 10.1002/lary.22180.

20.

Targeted next-generation sequencing of TP53 in oral tongue carcinoma from non-smokers.

Faden DL, Arron ST, Heaton CM, DeRisi J, South AP, Wang SJ.

J Otolaryngol Head Neck Surg. 2016 Sep 17;45(1):47. doi: 10.1186/s40463-016-0160-4.

Supplemental Content

Support Center